{"id":7673,"date":"2020-03-09T06:33:33","date_gmt":"2020-03-09T06:33:33","guid":{"rendered":"https:\/\/www.nicox.com\/nicox-approbation-de-vyzulta-solution-ophtalmique-de-latanoprostene-bunod-0024-a-taiwan-par-son-partenaire-licencie\/"},"modified":"2020-03-09T06:33:33","modified_gmt":"2020-03-09T06:33:33","slug":"nicox-approbation-de-vyzulta-solution-ophtalmique-de-latanoprostene-bunod-0024-a-taiwan-par-son-partenaire-licencie","status":"publish","type":"post","link":"https:\/\/www.nicox.com\/fr\/nicox-approbation-de-vyzulta-solution-ophtalmique-de-latanoprostene-bunod-0024-a-taiwan-par-son-partenaire-licencie\/","title":{"rendered":"Nicox : Approbation de VYZULTA\u00ae (solution ophtalmique de latanoprost\u00e8ne bunod), 0,024% \u00e0 Taiwan par son partenaire licenci\u00e9"},"content":{"rendered":"<p>Sophia Antipolis, France<\/p>\n<p><strong>Nicox SA<\/strong> (Euronext Paris : FR0013018124, COX, \u00e9ligible PEA-PME), soci\u00e9t\u00e9 internationale sp\u00e9cialis\u00e9e en ophtalmologie, annonce aujourd\u2019hui que son partenaire licenci\u00e9, Bausch + Lomb, a re\u00e7u l\u2019approbation de mise sur le march\u00e9 de VYZULTA\u00ae (solution ophtalmique de latanoprost\u00e8ne bunod), 0,024% \u00e0 Taiwan.<\/p>\n<p>Avec cette approbation suppl\u00e9mentaire, VYZULTA est maintenant approuv\u00e9 pour commercialisation dans six pays et territoires (\u00e0 savoir les \u00c9tats-Unis, l&rsquo;Argentine, le Canada, Hong Kong, le Mexique et Taiwan), ce qui marque la poursuite de l\u2019expansion de l\u2019approbation de VYZULTA dans des territoires o\u00f9 les autorit\u00e9s r\u00e9glementaires reconnaissent les donn\u00e9es cliniques de l\u2019enregistrement am\u00e9ricain (<em>New Drug Application,<\/em> NDA). VYZULTA est indiqu\u00e9 pour la r\u00e9duction de la pression intraoculaire (PIO) chez les patients atteints de glaucome \u00e0 angle ouvert ou d&rsquo;hypertension oculaire et est commercialis\u00e9 aux Etats-Unis et au Canada.<\/p>\n<p>Nicox re\u00e7oit des redevances nettes croissantes de 6% \u00e0 12% sur les ventes mondiales de VYZULTA ainsi que de futurs paiements d\u2019\u00e9tape pouvant atteindre un montant de 150 millions de dollars.<\/p>\n<p>Bausch + Lomb est une soci\u00e9t\u00e9 mondiale leader en sant\u00e9 oculaire de Bausch Health Companies Inc. (NYSE\/TSX: BHC).<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Sophia Antipolis, France Nicox SA (Euronext Paris : FR0013018124, COX, \u00e9ligible PEA-PME), soci\u00e9t\u00e9 internationale sp\u00e9cialis\u00e9e en ophtalmologie, annonce aujourd\u2019hui que son partenaire licenci\u00e9, Bausch + Lomb, a re\u00e7u l\u2019approbation de mise sur le march\u00e9 de VYZULTA\u00ae (solution ophtalmique de latanoprost\u00e8ne bunod), 0,024% \u00e0 Taiwan. Avec cette approbation suppl\u00e9mentaire, VYZULTA est maintenant approuv\u00e9 pour commercialisation dans [&hellip;]<\/p>\n","protected":false},"author":7,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[32,16],"tags":[],"class_list":["post-7673","post","type-post","status-publish","format-standard","hentry","category-actualites","category-actualites-et-media"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Nicox : Approbation de VYZULTA\u00ae (solution ophtalmique de latanoprost\u00e8ne bunod), 0,024% \u00e0 Taiwan par son partenaire licenci\u00e9 - Nicox<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.nicox.com\/fr\/nicox-approbation-de-vyzulta-solution-ophtalmique-de-latanoprostene-bunod-0024-a-taiwan-par-son-partenaire-licencie\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nicox : Approbation de VYZULTA\u00ae (solution ophtalmique de latanoprost\u00e8ne bunod), 0,024% \u00e0 Taiwan par son partenaire licenci\u00e9 - Nicox\" \/>\n<meta property=\"og:description\" content=\"Sophia Antipolis, France Nicox SA (Euronext Paris : FR0013018124, COX, \u00e9ligible PEA-PME), soci\u00e9t\u00e9 internationale sp\u00e9cialis\u00e9e en ophtalmologie, annonce aujourd\u2019hui que son partenaire licenci\u00e9, Bausch + Lomb, a re\u00e7u l\u2019approbation de mise sur le march\u00e9 de VYZULTA\u00ae (solution ophtalmique de latanoprost\u00e8ne bunod), 0,024% \u00e0 Taiwan. Avec cette approbation suppl\u00e9mentaire, VYZULTA est maintenant approuv\u00e9 pour commercialisation dans [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.nicox.com\/fr\/nicox-approbation-de-vyzulta-solution-ophtalmique-de-latanoprostene-bunod-0024-a-taiwan-par-son-partenaire-licencie\/\" \/>\n<meta property=\"og:site_name\" content=\"Nicox\" \/>\n<meta property=\"article:published_time\" content=\"2020-03-09T06:33:33+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/nicox-approbation-de-vyzulta-solution-ophtalmique-de-latanoprostene-bunod-0024-a-taiwan-par-son-partenaire-licencie\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/nicox-approbation-de-vyzulta-solution-ophtalmique-de-latanoprostene-bunod-0024-a-taiwan-par-son-partenaire-licencie\\\/\"},\"author\":{\"name\":\"\",\"@id\":\"\"},\"headline\":\"Nicox : Approbation de VYZULTA\u00ae (solution ophtalmique de latanoprost\u00e8ne bunod), 0,024% \u00e0 Taiwan par son partenaire licenci\u00e9\",\"datePublished\":\"2020-03-09T06:33:33+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/nicox-approbation-de-vyzulta-solution-ophtalmique-de-latanoprostene-bunod-0024-a-taiwan-par-son-partenaire-licencie\\\/\"},\"wordCount\":207,\"publisher\":{\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#organization\"},\"articleSection\":[\"Actualit\u00e9s\",\"Actualit\u00e9s et M\u00e9dia\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/nicox-approbation-de-vyzulta-solution-ophtalmique-de-latanoprostene-bunod-0024-a-taiwan-par-son-partenaire-licencie\\\/\",\"url\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/nicox-approbation-de-vyzulta-solution-ophtalmique-de-latanoprostene-bunod-0024-a-taiwan-par-son-partenaire-licencie\\\/\",\"name\":\"Nicox : Approbation de VYZULTA\u00ae (solution ophtalmique de latanoprost\u00e8ne bunod), 0,024% \u00e0 Taiwan par son partenaire licenci\u00e9 - Nicox\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#website\"},\"datePublished\":\"2020-03-09T06:33:33+00:00\",\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.nicox.com\\\/fr\\\/nicox-approbation-de-vyzulta-solution-ophtalmique-de-latanoprostene-bunod-0024-a-taiwan-par-son-partenaire-licencie\\\/\"]}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/\",\"name\":\"Nicox\",\"description\":\"Visible Science\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#organization\",\"name\":\"Nicox\",\"url\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Nicox\"},\"image\":{\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nicox : Approbation de VYZULTA\u00ae (solution ophtalmique de latanoprost\u00e8ne bunod), 0,024% \u00e0 Taiwan par son partenaire licenci\u00e9 - Nicox","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.nicox.com\/fr\/nicox-approbation-de-vyzulta-solution-ophtalmique-de-latanoprostene-bunod-0024-a-taiwan-par-son-partenaire-licencie\/","og_locale":"fr_FR","og_type":"article","og_title":"Nicox : Approbation de VYZULTA\u00ae (solution ophtalmique de latanoprost\u00e8ne bunod), 0,024% \u00e0 Taiwan par son partenaire licenci\u00e9 - Nicox","og_description":"Sophia Antipolis, France Nicox SA (Euronext Paris : FR0013018124, COX, \u00e9ligible PEA-PME), soci\u00e9t\u00e9 internationale sp\u00e9cialis\u00e9e en ophtalmologie, annonce aujourd\u2019hui que son partenaire licenci\u00e9, Bausch + Lomb, a re\u00e7u l\u2019approbation de mise sur le march\u00e9 de VYZULTA\u00ae (solution ophtalmique de latanoprost\u00e8ne bunod), 0,024% \u00e0 Taiwan. Avec cette approbation suppl\u00e9mentaire, VYZULTA est maintenant approuv\u00e9 pour commercialisation dans [&hellip;]","og_url":"https:\/\/www.nicox.com\/fr\/nicox-approbation-de-vyzulta-solution-ophtalmique-de-latanoprostene-bunod-0024-a-taiwan-par-son-partenaire-licencie\/","og_site_name":"Nicox","article_published_time":"2020-03-09T06:33:33+00:00","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"","Dur\u00e9e de lecture estim\u00e9e":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.nicox.com\/fr\/nicox-approbation-de-vyzulta-solution-ophtalmique-de-latanoprostene-bunod-0024-a-taiwan-par-son-partenaire-licencie\/#article","isPartOf":{"@id":"https:\/\/www.nicox.com\/fr\/nicox-approbation-de-vyzulta-solution-ophtalmique-de-latanoprostene-bunod-0024-a-taiwan-par-son-partenaire-licencie\/"},"author":{"name":"","@id":""},"headline":"Nicox : Approbation de VYZULTA\u00ae (solution ophtalmique de latanoprost\u00e8ne bunod), 0,024% \u00e0 Taiwan par son partenaire licenci\u00e9","datePublished":"2020-03-09T06:33:33+00:00","mainEntityOfPage":{"@id":"https:\/\/www.nicox.com\/fr\/nicox-approbation-de-vyzulta-solution-ophtalmique-de-latanoprostene-bunod-0024-a-taiwan-par-son-partenaire-licencie\/"},"wordCount":207,"publisher":{"@id":"https:\/\/www.nicox.com\/fr\/#organization"},"articleSection":["Actualit\u00e9s","Actualit\u00e9s et M\u00e9dia"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/www.nicox.com\/fr\/nicox-approbation-de-vyzulta-solution-ophtalmique-de-latanoprostene-bunod-0024-a-taiwan-par-son-partenaire-licencie\/","url":"https:\/\/www.nicox.com\/fr\/nicox-approbation-de-vyzulta-solution-ophtalmique-de-latanoprostene-bunod-0024-a-taiwan-par-son-partenaire-licencie\/","name":"Nicox : Approbation de VYZULTA\u00ae (solution ophtalmique de latanoprost\u00e8ne bunod), 0,024% \u00e0 Taiwan par son partenaire licenci\u00e9 - Nicox","isPartOf":{"@id":"https:\/\/www.nicox.com\/fr\/#website"},"datePublished":"2020-03-09T06:33:33+00:00","inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.nicox.com\/fr\/nicox-approbation-de-vyzulta-solution-ophtalmique-de-latanoprostene-bunod-0024-a-taiwan-par-son-partenaire-licencie\/"]}]},{"@type":"WebSite","@id":"https:\/\/www.nicox.com\/fr\/#website","url":"https:\/\/www.nicox.com\/fr\/","name":"Nicox","description":"Visible Science","publisher":{"@id":"https:\/\/www.nicox.com\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.nicox.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.nicox.com\/fr\/#organization","name":"Nicox","url":"https:\/\/www.nicox.com\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.nicox.com\/fr\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Nicox"},"image":{"@id":"https:\/\/www.nicox.com\/fr\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":""}]}},"_links":{"self":[{"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/posts\/7673","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/comments?post=7673"}],"version-history":[{"count":0,"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/posts\/7673\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/media?parent=7673"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/categories?post=7673"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/tags?post=7673"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}